Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories recorded a robust sales performance, with Nutrition sales reaching $2.15 billion, representing a 6.8% year-over-year organic growth that exceeded consensus expectations. The company's Structural Heart portfolio showcased remarkable resilience, with an organic growth of 14.7%, further indicating strong market adoption and an anticipated continuation of growth in the teens. Additionally, Abbott's commitment to dividends, having increased for over 50 consecutive years, reinforces investor confidence alongside an optimistic outlook for organic sales growth projected at 7.5-8.5% for 2025.

Bears say

Abbott Laboratories has experienced a notable decline in diagnostics revenue, reporting $2.054 billion, which fell short of expectations due to lower-than-anticipated COVID-19 testing sales and adverse impacts from volume-based procurement programs in China. First-quarter 2025 sales of $10.36 billion, while showing a year-over-year increase, slightly missed projections due to the same COVID-related issues and soft performance in diagnostics products. Additionally, macroeconomic pressures such as inflation, foreign exchange challenges, and potential regulatory hurdles present significant risks that may hinder Abbott's growth and earnings potential moving forward.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $145.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $145.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.